Krissy Wright joins as CFO and Sandra Statz as EVP of Regulatory Affairs to Support Company’s Mission to Create a World Without Heart Attacks
New York – May 1, 2023 -- Cleerly, the company creating a new standard of care for heart disease, announced today it has appointed Krissy Wright as Chief Financial Officer (CFO) and Sandra Statz as Executive Vice President of Regulatory Affairs. In her role, Wright will provide financial supervision to the business and ensure adherence. Statz will oversee global regulatory strategy and submissions in compliance with applicable regulatory requirements and in alignment with Cleerly’s goals.
“We are incredibly privileged to add two celebrated business leaders to the Cleerly executive team,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “Their proven track record of strategic and operational experience in finance and regulatory affairs will extend our team’s expertise to serve Cleerly’s mission to create a world without heart attacks.”
Wright has over 20 years of experience in finance and corporate development leadership. Most recently, she served as Vice President and General Manager of Brain Modulation at Medtronic, and previously was Vice President and Chief Financial Officer for the Neuromodulation Operating Unit of Medtronic, both in finance and corporate development. Prior to Medtronic, Wright worked at PricewaterhouseCoopers in the Audit and Assurance and Transaction Services practices for 11 years. She earned her bachelor’s degree from the University of Minnesota, and MBA from the Fuqua School of Business at Duke University.
“I am thrilled to be joining Cleerly as its new CFO,” Wright said. “I am looking forward to working with this accomplished leadership team to change the paradigm of cardiovascular care. Leveraging financial and operational rigor, I am committed to building a finance function that supports the company’s strategic objectives and helps to drive long-term value creation.”
Statz brings more than 30 years of experience in oncology and molecular diagnostics. Before joining Cleerly, she served as Senior Vice President, Clinical & Regulatory Affairs at Exact Sciences Corporation. She also served as Vice President, Clinical, Quality & Regulatory at Exact Sciences, as well as Sr. Director, Clinical Affairs. Additionally, she spent seven years at Quintiles, where she last held the Director, Clinical Operations position. Statz earned bachelor’s and master's degrees from the University of Wisconsin-Madison and has been published nine times, with a focus on cancer research.
“I am incredibly honored to join Cleerly and be part of this contribution to transforming cardiac preventative care,” Statz said. “Cleerly’s commitment to top grade evidence is essential to regulatory success, and I am committed to ongoing success to ensure patient access to this life saving cardiovascular technology.”
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.
 Download: JPG |
Cleerly: March 26, 2024
CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA
Cleerly: March 5, 2024
Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial
Cleerly: February 22, 2024
FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
Cleerly
